Key result
Advances in cardiac transplant management substantially improve long-term survival over a 10-year span.
Answers are grounded in this paper and cite their sources.
Changes in the management of cardiac transplant recipients over the past 10 years have resulted in a substantial improvement in the outlook for survival. Imuran and prednisone remain the primary immunosuppressive agents, but rabbit antihuman thymocyte globulin is used initially and reinstituted during rejection. Endomyocardial biopsy has allowed more precise diagnosis and management of rejection, and more recently immunological monitoring has been introduced to provide more frequent assessment of the host immune response. Infection is the major cause of death, and its diagnosis and treatment is managed aggressively. Current survival figures justify the use of cardiac transplantation, by an experienced team, when other measures have been exhausted.
No takes yet. Share an insight, caveat, or question.
Jamieson et al. (1979) conducted a review in Cardiac transplantation. Immunosuppressive therapy (azathioprine, prednisone, rabbit antihuman thymocyte globulin), endomyocardial biopsy, and immunological monitoring was evaluated on Survival. Advances in cardiac transplant management over 10 years, including endomyocardial biopsy, immunological monitoring, and aggressive infection control, substantially improved survival.
Synapse has enriched 10 related papers. Consider them for comparative context: